Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 16/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.87 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180856 | 1.00 | CHRM2 (0.87) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4879759 | 0.85 | CHRM3 (0.67) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4084970 | 0.84 | CHRM2 (0.72) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4084084 | 0.84 | CHRM2 (0.72) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948020 | 0.83 | CHRM2 (0.71) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948227 | 0.83 | CHRM2 (0.71) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6585812 | 0.82 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948401 | 0.82 | CHRM2 (0.69) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948399 | 0.82 | CHRM2 (0.69) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6589582 | 0.81 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | claimed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | claimed |
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | disclosed |
| EP-1583741-A1 | 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories, Limited (IN) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004056767-A1 | 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | CHRM3, CHRM1, CHRM5 | CHRM2 4/4885CHRM1 2/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.